Patents Assigned to Universitaet Bern
-
Patent number: 11919943Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.Type: GrantFiled: October 25, 2022Date of Patent: March 5, 2024Assignees: MEMO THERAPEUTICS AG, UNIVERSITÄT BERN, UNIVERSITÄT ZÜRICHInventors: Marcel Weber, Simone Schmitt, Christoph Esslinger, Thomas Schachtner, Uyen Huynh-Do, Maurizio Provenzano
-
Publication number: 20230372726Abstract: The present invention relates to a magnetic field exposure system for use in exposing organic cells, cellular tissue or at least a part of a subject to a low frequency magnetic field. The system includes a magnetic field generator and amplifier feeding one or more electromagnetic coils configured to produce a magnetic field that varies according to an amplitude modulated signal with a carrier frequency of from 360 to 450. Hz, wherein the modulation frequency is from 0.5 to 100. Hz; and wherein the MF has a field strength of from 0.5 to 250 ?T.Type: ApplicationFiled: March 26, 2021Publication date: November 23, 2023Applicant: Universität BernInventors: Eliane J. Müller, William Hariton, Brigitte Brunner
-
Patent number: 11820971Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.Type: GrantFiled: July 25, 2022Date of Patent: November 21, 2023Assignees: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBHInventors: Ute Schaeper, Sibylle Dames, Eliot Morrison, Raja Prince Eladnani, Anne Angelillo-Scherrer
-
Patent number: 11723913Abstract: The invention provides an siRNA against protein S for use in a method of treatment of hemophilia. Also within the scope of the present invention is a method for treating hemophilia in a patient in need thereof, comprising administering to the patient a molecule comprising a siRNA according to the invention, and a dosage form for the prevention or treatment of hemophilia, comprising a molecule comprising a siRNA according to the invention.Type: GrantFiled: November 2, 2017Date of Patent: August 15, 2023Assignee: Universität BernInventors: Raja Prince El Adnani, Anne Angelillo-Scherrer
-
Publication number: 20230173025Abstract: The present invention relates to Fetuin A (AHSG) for use in a method for treating a renal disorder, wherein an amount of Fetuin A effective for treating the renal disorder is administered to a subject in need thereof. The present invention further relates to a pharmaceutical composition for use in treating a renal disorder comprising Fetuin A and optionally at least one pharmaceutical acceptable carrier.Type: ApplicationFiled: March 11, 2021Publication date: June 8, 2023Applicant: Universitaet BernInventors: Uyen Huynh-Do, Stefan Rudloff
-
Patent number: 11655439Abstract: A cell culturing system includes a docking station, a handling unit, a culturing module and an actuation layer. The culturing module has a culturing well and a culturing membrane separating the culturing well in an apical culturing chamber and a basal culturing chamber. The handling unit removably accommodates the culturing module and the actuation layer. The docking station has a coupling structure for removably holding the handling unit in a predefined position and an actuation feeding channel, wherein, when the handling unit is held by the coupling structure in the predefined position, a first end of the actuation feeding channel is connected to the actuation bore and a second end of the actuation feeding channel is connected to a connector.Type: GrantFiled: November 23, 2017Date of Patent: May 23, 2023Assignees: ALVEOLIX TECHNOLOGIES AG, UNIVERSITÄT BERNInventors: Olivier Thierry Guenat, Janick Daniel Stucki, Marcel Aeschlimann, Christophe Léchot
-
Publication number: 20230087264Abstract: The invention relates to a method for obtaining a visual field map of an observer, particularly a perimetry method, wherein a plurality of test locations in front of the observer is provided, at each test location of a subset of said plurality a respective perceived sensitivity threshold 5 is measured, wherein at least one light signal is provided at the respective test location, and wherein it is monitored whether said observer observes said at least one light signal, and wherein for each test location a respective estimate of the perceived sensitivity threshold is derived from the previously measured perceived sensitivity thresholds of said subset, and wherein said light signal is provided at a light intensity value derived from the estimate of the 10 perceived sensitivity threshold of said respective test location.Type: ApplicationFiled: October 14, 2022Publication date: March 23, 2023Applicant: UNIVERSITÄT BERNInventors: Serife Seda KUCUR, Raphael SZNITMAN
-
Publication number: 20230031648Abstract: The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.Type: ApplicationFiled: September 30, 2022Publication date: February 2, 2023Applicant: UNIVERSITAET BERNInventors: Eduard BABIYCHUK, Annette DRAEGER
-
Publication number: 20230019513Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.Type: ApplicationFiled: July 25, 2022Publication date: January 19, 2023Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBHInventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
-
Publication number: 20220363687Abstract: The present invention relates to compounds of formula 1 or 2, wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of formula 1 or 2. Compounds of formula 1 or 2 are Janus kinase inhibitors and thus useful in the treatment of a disease, particularly an autoimmune disease, cancer, Alzheimer's disease or useful in preventing the rejection of an allograft or xenograft.Type: ApplicationFiled: September 2, 2020Publication date: November 17, 2022Applicant: UNIVERSITÄT BERNInventors: Kris MEIER, Jean-Louis REYMOND
-
Publication number: 20220340899Abstract: The invention relates to stereoselective peptide dendrimers for nucleic acid transfection comprising the formula (D3)8-(B3-D2)4-(B2-D1)2-B1—Z (1), wherein Z is a hydrophobic core with Z being —XY1 (1a), —XY2XY2 (1b), —XY3Cys (1c) or —HP (1d), X is selected from Lys or Glu, and each Y is fatty or amine acids, HP is a hydrophobic peptide consisting of 3 to 5 hydrophobic amino, B is Lys and each D independently from any other D is a dipeptide consisting of one hydrophobic amino acid and one cationic amino acid (HC or CH), a dipeptide consisting of two cationic amino acids (CC) or a dipeptide consisting of two hydrophobic amino acids (HH). The invention further comprises a method for transfecting a cell (ex vivo) using the above-mentioned dendrimer.Type: ApplicationFiled: August 7, 2020Publication date: October 27, 2022Applicant: UNIVERSITÄT BERNInventors: Jean-Louis REYMOND, Marc HEITZ, Tamis DARBRE, Susanna ZAMOLO
-
Patent number: 11473045Abstract: A device for in-vitro modelling in-vivo tissues of organs that includes a first body portion with at least one access chamber, a second body portion with at least one culturing chamber, and a culturing membrane dividing the at least one access chamber from the culturing chamber. The device further includes a third body portion with at least one actuation chamber having at least one limitation cavity, and an actuation membrane dividing the at least one culturing chamber from the at least one actuation chamber. With the device, a robust actuation system can be provided that does not depend on the mechanical properties of the actuation membrane material, nor on the pressure, and that allows to mimic three-dimensional deformations of the tissue, in particular of lung alveoli.Type: GrantFiled: July 31, 2018Date of Patent: October 18, 2022Assignee: Universität BernInventors: Olivier Thierry Guenat, Marcel Felder, Andreas Stucki, Janick Daniel Stucki, Thomas Geiser
-
Patent number: 11471040Abstract: The invention relates to a method for obtaining a visual field map of an observer, particularly a perimetry method, wherein a plurality of test locations in front of the observer is provided, at each test location of a subset of said plurality a respective perceived sensitivity threshold is measured, wherein at least one light signal is provided at the respective test location, and wherein it is monitored whether said observer observes said at least one light signal, and wherein for each test location a respective estimate of the perceived sensitivity threshold is derived from the previously measured perceived sensitivity thresholds of said subset, and wherein said light signal is provided at a light intensity value derived from the estimate of the perceived sensitivity threshold of said respective test location.Type: GrantFiled: September 18, 2018Date of Patent: October 18, 2022Assignee: UNIVERSITÄT BERNInventors: Serife Seda Kucur, Raphael Sznitman
-
Patent number: 11430557Abstract: An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.Type: GrantFiled: March 16, 2018Date of Patent: August 30, 2022Assignees: UNIVERSITÄT BERN, DEBIOTECH S.A.Inventors: Stavroula Mougiakakou, Qingnan Sun, Marko Jankovic, Laurent-Dominique Piveteau, Stephan Proennecke, João Budzinski
-
Publication number: 20220243202Abstract: The invention relates to nucleic acid products that interfere with PROS1 gene expression or inhibit its expression. The nucleic acids are particularly for use in the treatment, prevention or reduction of risk of suffering from a bleeding disorder.Type: ApplicationFiled: May 6, 2020Publication date: August 4, 2022Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBHInventors: Sibylle DAMES, Ute SCHAEPER, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
-
Publication number: 20220135974Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.Type: ApplicationFiled: November 11, 2021Publication date: May 5, 2022Applicants: UNIVERSITÄT BERN, SILENCE THERAPEUTICS GMBHInventors: Ute SCHAEPER, Sibylle DAMES, Eliot MORRISON, Raja PRINCE ELADNANI, Anne ANGELILLO-SCHERRER
-
Publication number: 20220087934Abstract: The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two-and a four-component mixture of lipo somes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected in travenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Strepto-coccus pneumoniae.Type: ApplicationFiled: November 30, 2021Publication date: March 24, 2022Applicant: UNIVERSITAET BERNInventors: Eduard BABIYCHUK, Annette DRAEGER
-
Publication number: 20220072285Abstract: The invention relates to an implantable valve (1) for a drainage system for discharging cerebrospinal fluid, comprising: a valve housing (10) extending along a valve axis (A), an inlet (2) and an outlet (3) as well as a valve housing (10) surrounding an interior space (4), a valve body assembly (600) arranged in the interior (4) and movably arranged in the interior space (4), a first valve seat (5), wherein the valve body assembly (600) is configured to abut the first valve seat (5) to close a flow connection between the inlet (2) and the interior space (4) of the valve housing (10), a second valve seat (7) which faces the first valve seat (5), wherein the valve body assembly (600) is configured to abut the second valve seat (7) to close a flow connection between the outlet (3) and the interior space (4) of the valve housing (10), and a spring device (800) arranged in the interior space (4) which exerts a spring force on the valve body assembly (600) in the direction of the first valve seat (5).Type: ApplicationFiled: December 27, 2019Publication date: March 10, 2022Applicants: UNIVERSITÄT BERNInventors: Andreas SPIEGELBERG, Jürgen BECK
-
Patent number: 11220530Abstract: The present invention relates to a nanosphere comprising an equal number of a human SEC14-like protein and a cognate ligand of said SEC14-like protein as well as to methods of producing the same and uses of said nanospheres.Type: GrantFiled: January 24, 2017Date of Patent: January 11, 2022Assignee: UNIVERSITÄT BERNInventor: Achim Stocker
-
Patent number: 11207390Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of a condition or disorder selected from a pruritic condition or an allergic condition, of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating pruritus, preferably pruritus associated with a pruritic condition or an allergic condition such as allergic dermatitis, of equine mammals, preferably of horses.Type: GrantFiled: March 7, 2018Date of Patent: December 28, 2021Assignees: UNIVERSITÄT ZÜRICH, EVAX AG, UNIVERSITÄT BERNInventors: Antonia Fettelschoss, Victoria Fettelschoss, Martin Bachmann